The final, formatted version of the article will be published soon.
BRIEF RESEARCH REPORT article
Front. Cell. Infect. Microbiol.
Sec. Molecular Viral Pathogenesis
Volume 15 - 2025 |
doi: 10.3389/fcimb.2025.1527573
This article is part of the Research Topic Emerging concepts for respiratory viruses after the pandemic View all 3 articles
Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children
Provisionally accepted- 1 Faculty of Medicine, University of Buenos Aires, Buenos Aires, Buenos Aires, Argentina
- 2 Hospital Universitario Austral, Buenos Aires, Buenos Aires, Argentina
- 3 Hospital Pedro de Elizalde, Buenos Aires, Buenos Aires, Argentina
- 4 Hospital Posadas, Buenos Aires, Buenos Aires, Argentina
- 5 Clínica del Niño de Quilmes, Quilmes, Argentina
- 6 Hospital Juan Pablo II, Corrientes, Corrientes, Argentina
- 7 National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
Background. Most children in Argentina received only the initial COVID-19 vaccine series, with presumed hybrid immunity after multiple Omicron waves. However, the durability of immune memory, particularly in immunocompromised (IC) children, remains poorly studied.Methods. A cohort of IC (n=45) and healthy children (HC, n=79) was assessed between 13 to 17 months after receiving two or three doses of BBIBP-CorV and/or BNT162b2.Plasma anti-spike IgG, neutralizing activity and antigen-specific CD4+ and CD8+ T cells against Wuhan and Omicron BA.5 variants were assessed.Results. Most children remained seropositive after two vaccine doses, but compared with HC, IC exhibited lower neutralizing titers against both Wuhan and Omicron BA.5, particularly those vaccinated with BBIBP-CorV. Even after three vaccine doses, IC showed weaker neutralizing antibody response, CD8+ T cell responses and lower IFN-γ production compared with HC. Integrated analysis of neutralizing antibodies, memory CD4⁺, and CD8⁺ T cells revealed a weak immune memory among IC with an important compromise in memory CD8⁺ T cell responses.Conclusions. Immunity can last up to 17 months, but reduced effectiveness against new variants highlights the need for updated COVID-19 vaccines, especially for IC children.
Keywords: Children, SARS-CoV-2, variants, Vaccines, antibodies, T cells
Received: 13 Nov 2024; Accepted: 21 Jan 2025.
Copyright: © 2025 Russo, Otero, Uranga, Seery, Raiden, Algieri, De Carli, Borda, Albistur, Heinitz, Marcó Del Pont, Pardini, Budano, Alvarez, Simaz, Merhar, Quintana, Garbini, Portela, Pereira, Ferrero, Geffner and Arruvito. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lourdes Arruvito, National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.